Officer and Director Transactions

Raphael Deferiere, Chief Accounting Officer of Centessa Pharmaceuticals plc, reported transactions on June 24, 2026. The company was acquired by Eli Lilly and Company through a scheme of arrangement. Deferiere had 11,000 ordinary shares disposed of, with a post-transaction amount of 0 shares. Additionally, two share option transactions were reported: 165,000 options with an exercise price of $13.41 and 42,000 options with an exercise price of $25.19 were disposed of, both with a post-transaction amount of 0 shares. These transactions were part of the acquisition where shareholders received $38.00 in cash and a contingent value right (CVR) per share.